Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.090 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Lexaria Bioscience Corp < Previous 1 2 3 4 5 Next > Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B December 13, 2021 Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s... Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session December 10, 2021 Gainers Reshape Lifesciences (NASDAQ:RSLS... Via Benzinga 52 Biggest Movers From Yesterday December 09, 2021 Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... Via Benzinga Why Lexaria Shares Are Rising Today December 08, 2021 Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We... Via Benzinga Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference December 08, 2021 Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of... Via Benzinga 35 Stocks Moving In Wednesday's Mid-Day Session December 08, 2021 Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options... Via Benzinga Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket? December 08, 2021 Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session December 08, 2021 Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7... Via Benzinga Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD December 03, 2021 Lexaria Bioscience Corp. (NASDAQ: Via Benzinga Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study November 29, 2021 Lexaria Bioscience Corp Via Benzinga Lexaria Bioscience's DehydraTECH(TM) Drug Delivery Tech Finding Multiple Applications November 24, 2021 Lexaria intends to undertake its most ambitious study yet – HYPER-H21-4 – as it pursu... Via Benzinga Lexaria Bioscience Announces 2022 DehydraTECH(TM) R&D Programs November 18, 2021 Lexaria’s 2022 R&D programs are set to include research on hormone replacement, dementia, rheumatoid disease, and diabetes, among other conditions The program builds... Via Benzinga Lexaria Bioscience Corp. Embarks on Ambitious Hypertension Clinical Study November 15, 2021 Lexaria has embarked on its HYPER-H21-4 study, its fourth hypertension clinical study, and its most ambitious yet This study builds on the HYPER-H21-1 and HYPER-H21-2 findings,... Via Benzinga Lexaria Expands 2022 R&D Programs to Evaluate Alzheimer's, Diabetes November 11, 2021 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced its plans for several new and ongoing DehydraTECH(TM)-applied R&D programs... Via Benzinga Lexaria Bioscience Corp. Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology's Efficacy in Reducing/Inhibiting Seizure Activity November 04, 2021 Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD h... Via Benzinga Lexaria Bioscience Corp. to Expand Hypertension Clinical Program Through Most Ambitious Study to Date November 03, 2021 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, today announced a significant new study to expand its hypertension clinical program. In addition... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session November 03, 2021 Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... Via Benzinga Lexaria Bioscience Corp. Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex November 02, 2021 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has begun a new study, EPIL-A21-1, designed to evaluate whether its DehydraTECH(TM)-CBD (“... Via Benzinga Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures November 01, 2021 Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure... Via Benzinga Lexaria Bioscience Corp.'s DehydraTECH(TM) Addresses the Needs of Medical THC Users October 26, 2021 Lexaria’s THC absorption animal study yielded promising results on the patented DehydraTECH(TM) technology It showed that the technology required a shorter time to deliver... Via Benzinga Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension September 08, 2021 Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH... Via Benzinga Exposures Product Safety CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction September 07, 2021 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented... Via Benzinga Why Lexaria Bioscience Shares Are Trading Higher Today September 07, 2021 Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session September 07, 2021 Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2... Via Benzinga Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients September 07, 2021 Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential... Via Benzinga Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology September 02, 2021 Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral... Via Benzinga Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months July 29, 2021 Image by Lucas Vasques on Unsplash Biotech company Lexaria Bioscience Corp. (NASDAQ: LEXX) has been making news for DehydraTECH™ — its proprietary disruptive and cost-... Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session July 27, 2021 Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2... Via Benzinga 38 Stocks Moving In Thursday's Mid-Day Session July 22, 2021 Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares climbed 129.7% to $12.75 after the company announced new results from its TATX-03 PolyTope Therapy, demonstrating... Via Benzinga 61 Biggest Movers From Yesterday July 23, 2021 Gainers ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) shares jumped 138.2% to close at $13.22 on Thursday after the company announced new results from its TATX-03 PolyTope Therapy... Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.